Cargando…

Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma

OBJECTIVE: To describe recovery of adrenal insufficiency in asthmatic children treated with inhaled corticosteroids (ICS) and cortisol replacement therapy. DESIGN: Retrospective, observational study. PATIENTS: A total of 113 patients, 74 male; age 10.4 (3.3–16.5) years; beclomethasone-equivalent ICS...

Descripción completa

Detalles Bibliográficos
Autores principales: Gangadharan, Arundoss, McCoy, Paul, Phyo, Aye, McGuigan, Michael P, Dharmaraj, Poonam, Ramakrishnan, Renuka, McNamara, Paul S, Blair, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735982/
https://www.ncbi.nlm.nih.gov/pubmed/29290688
http://dx.doi.org/10.2147/JAA.S142874
_version_ 1783287308768772096
author Gangadharan, Arundoss
McCoy, Paul
Phyo, Aye
McGuigan, Michael P
Dharmaraj, Poonam
Ramakrishnan, Renuka
McNamara, Paul S
Blair, Joanne
author_facet Gangadharan, Arundoss
McCoy, Paul
Phyo, Aye
McGuigan, Michael P
Dharmaraj, Poonam
Ramakrishnan, Renuka
McNamara, Paul S
Blair, Joanne
author_sort Gangadharan, Arundoss
collection PubMed
description OBJECTIVE: To describe recovery of adrenal insufficiency in asthmatic children treated with inhaled corticosteroids (ICS) and cortisol replacement therapy. DESIGN: Retrospective, observational study. PATIENTS: A total of 113 patients, 74 male; age 10.4 (3.3–16.5) years; beclomethasone-equivalent ICS dose, 800 μg, (100–1,000), tested by low dose short Synacthen (tetracosactide) test (LDSST), were studied. Test results were classified by basal and peak cortisol concentration: “normal” (basal >100 nmol/L, peak >500 nmol/L), “suboptimal” (basal >100 nmol/L, peak 350–499 nmol/L), “abnormal” (basal <100 nmol/L and/or peak <350 nmol/L). Patients with suboptimal results received hydrocortisone during periods of stress only, and those with abnormal responses received daily hydrocortisone, increased during periods of stress. A total of 73 patients (68%) had ≥2 LDSSTs over 2.2 years (0.2–7.7). MEASUREMENTS: Change in cortisol response to repeat LDSST (movement between diagnostic groups, difference in basal and peak cortisol >15% [2× the inter-assay coefficient of variation]), change in BMI and height standard deviation score (SDS). RESULTS: Baseline test results were abnormal in 17 patients (15%) and all of them had repeat tests. In 13 patients (76%), test results improved (normal in six, suboptimal in seven) and four (24%) remained abnormal. Baseline tests results were suboptimal in 54 patients (48%), of whom 50 (93%) were retested. Repeat tests were normal in 36 patients (72%), remained suboptimal in 11 (22%), and were abnormal in three (6%). Baseline tests results were normal in 42 patients, of whom six patients (14%) were retested. Results remained normal in three (50%), were suboptimal in two (33%), and abnormal in one (17%). Basal and peak cortisol levels increased by >15% in 33/73 (45%) and 42/73 (57%) patients, respectively, and decreased by >15% in 14/73 (19%) and 7/73 (10%), respectively. There was no significant change in height or BMI SDS. CONCLUSION: Recovery of adrenal function is common and occurs during continued ICS and cortisol replacement therapy.
format Online
Article
Text
id pubmed-5735982
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57359822017-12-29 Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma Gangadharan, Arundoss McCoy, Paul Phyo, Aye McGuigan, Michael P Dharmaraj, Poonam Ramakrishnan, Renuka McNamara, Paul S Blair, Joanne J Asthma Allergy Original Research OBJECTIVE: To describe recovery of adrenal insufficiency in asthmatic children treated with inhaled corticosteroids (ICS) and cortisol replacement therapy. DESIGN: Retrospective, observational study. PATIENTS: A total of 113 patients, 74 male; age 10.4 (3.3–16.5) years; beclomethasone-equivalent ICS dose, 800 μg, (100–1,000), tested by low dose short Synacthen (tetracosactide) test (LDSST), were studied. Test results were classified by basal and peak cortisol concentration: “normal” (basal >100 nmol/L, peak >500 nmol/L), “suboptimal” (basal >100 nmol/L, peak 350–499 nmol/L), “abnormal” (basal <100 nmol/L and/or peak <350 nmol/L). Patients with suboptimal results received hydrocortisone during periods of stress only, and those with abnormal responses received daily hydrocortisone, increased during periods of stress. A total of 73 patients (68%) had ≥2 LDSSTs over 2.2 years (0.2–7.7). MEASUREMENTS: Change in cortisol response to repeat LDSST (movement between diagnostic groups, difference in basal and peak cortisol >15% [2× the inter-assay coefficient of variation]), change in BMI and height standard deviation score (SDS). RESULTS: Baseline test results were abnormal in 17 patients (15%) and all of them had repeat tests. In 13 patients (76%), test results improved (normal in six, suboptimal in seven) and four (24%) remained abnormal. Baseline tests results were suboptimal in 54 patients (48%), of whom 50 (93%) were retested. Repeat tests were normal in 36 patients (72%), remained suboptimal in 11 (22%), and were abnormal in three (6%). Baseline tests results were normal in 42 patients, of whom six patients (14%) were retested. Results remained normal in three (50%), were suboptimal in two (33%), and abnormal in one (17%). Basal and peak cortisol levels increased by >15% in 33/73 (45%) and 42/73 (57%) patients, respectively, and decreased by >15% in 14/73 (19%) and 7/73 (10%), respectively. There was no significant change in height or BMI SDS. CONCLUSION: Recovery of adrenal function is common and occurs during continued ICS and cortisol replacement therapy. Dove Medical Press 2017-12-15 /pmc/articles/PMC5735982/ /pubmed/29290688 http://dx.doi.org/10.2147/JAA.S142874 Text en © 2017 Gangadharan et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Gangadharan, Arundoss
McCoy, Paul
Phyo, Aye
McGuigan, Michael P
Dharmaraj, Poonam
Ramakrishnan, Renuka
McNamara, Paul S
Blair, Joanne
Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma
title Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma
title_full Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma
title_fullStr Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma
title_full_unstemmed Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma
title_short Recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma
title_sort recovery of hypothalamo–pituitary–adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735982/
https://www.ncbi.nlm.nih.gov/pubmed/29290688
http://dx.doi.org/10.2147/JAA.S142874
work_keys_str_mv AT gangadharanarundoss recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma
AT mccoypaul recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma
AT phyoaye recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma
AT mcguiganmichaelp recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma
AT dharmarajpoonam recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma
AT ramakrishnanrenuka recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma
AT mcnamarapauls recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma
AT blairjoanne recoveryofhypothalamopituitaryadrenalaxissuppressionduringtreatmentwithinhaledcorticosteroidsforchildhoodasthma